Pharmaceutical intermediates

Moxifloxacin hydrochloride Intermediates

2 pharmaceutical intermediates for Moxifloxacin hydrochloride. Indication: Bacterial conjunctivitis; Sinusitis; Pneumonia; Respiratory tract infection.

Submit a Project All intermediates

About Moxifloxacin hydrochloride

Originator: Bayer Healthcare Pharmaceuticals Inc
Indication: Bacterial conjunctivitis; Sinusitis; Pneumonia; Respiratory tract infection
Approved Date: 12/10/1999

Available intermediates

2 intermediates currently listed for Moxifloxacin hydrochloride. Request specifications, documentation or a quotation for any item below.

Moxifloxacin hydrochloride intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester	112811-71-9	/	/
CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE	151213-40-0	/	/

Other programs under M

Maribavir Maxacalcitol Metoclopramide HCl Micafungin Sodium Milvexian Mirogabalin besilate Molnupiravir Momelotinib Dihydrochloride Monohydrate

Building toward Moxifloxacin hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here